Physician profile
Michael E Joseph
NPI 1902919178
$94,367.79
in general payments reported to CMS, 2019-2025
34 companies · $1,352 in 2025
The $1,352 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $1,417 · 2021: $86K · 2022: $1,407 · 2023: $1,372 · 2024: $1,218 · 2025: $1,352.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,872 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,871.51 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apria Healthcare LLC | $85,260.00 | 2021 | |
| Amgen INC. | $2,166.61 | 2019-2025 | Enbrel, Otezla, Krystexxa |
| Glaxosmithkline, LLC. | $1,333.62 | 2019-2025 | Benlysta, Nucala, Trelegy Ellipta |
| Pfizer INC. | $901.73 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $812.21 | 2020-2025 | Acthar |
| Abbvie INC. | $642.12 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $541.30 | 2019-2025 | |
| Janssen Biotech, INC. | $447.49 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $394.53 | 2019-2022 | |
| Octapharma USA, INC. | $263.62 | 2019-2023 | Cutaquig |
| Astrazeneca Pharmaceuticals Lp | $254.10 | 2019-2025 | Saphnelo, Fasenra, Tezspire |
| Mallinckrodt Enterprises LLC | $190.42 | 2019 | |
| Genentech USA, INC. | $170.25 | 2019-2023 | Rituxan, Actemra |
| Horizon Therapeutics Plc | $164.98 | 2019-2023 | Krystexxa |
| Radius Health, INC. | $146.76 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $82.75 | 2019-2023 | |
| Shire North American Group INC | $78.02 | 2019 | |
| Ucb, INC. | $73.53 | 2022-2025 | Bimzelx |
| Ani Pharmaceuticals, INC. | $70.98 | 2022-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $65.48 | 2020-2024 | |
| Csl Behring | $51.68 | 2020-2021 | |
| Grifols USA, LLC | $47.52 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.60 | 2019-2021 | |
| Kaleo, INC. | $24.89 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $24.36 | 2021 | |
| Sandoz INC. | $23.93 | 2024 | Hyrimoz |
| Bayer Healthcare Pharmaceuticals INC. | $17.73 | 2022 | |
| Fresenius Kabi USA, LLC | $14.42 | 2024 | Idacio |
| Optinose US, INC. | $13.35 | 2021 | |
| Zyla Life Sciences, INC. | $12.26 | 2019 | |
| Lilly USA, LLC | $12.20 | 2020 | |
| Hospira, INC. | $8.81 | 2024 | |
| Organon LLC | $8.01 | 2021 | |
| Bio Products Laboratory USA, INC. | $2.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.